PLT Test Blog

Piperine/Pepper             Resveratrol/Red wine          Sunitinib/Sutent    This post is all about lowering chloride within neurons, by increasing the expression of the transporter that lets it leave, called KCC2. Today’s post is one I never finished writing from last year; I looked up the price of Sutent/Sunitinib and then I remembered why. It does again highlight how cancer drugs, when they become cheap generics, will provide interesting options for autism treatment. It also shows again how Rett Syndrome is getting attention from researchers. It also highlights that really clever Americans are looking for bumetanide alternatives, in the false belief that bumetanide has troubling side effects that cannot be managed/mitigated. The study is by some clever guys in Cambridge Massachusetts. Another group of clever guys from MIT burned through $40 million dollars a few years ago trying to develop R-Baclofen for Fragile-X...

Rathaus/City Hall in Hanover, Germany       Attribution:  Thomas Wolf,  www.foto-tw.de The short version of this post is that the old German diuretic Azosemide delivers the same autism benefit as the popular diuretic Bumetanide, but it has a different profile of diuresis.   Azosemide may indeed be more potent at blocking NKCC1 in the brain, but this needs to be investigated/confirmed.   For some people Azosemide will be a better choice than Bumetanide. The bulk of today’s post is really likely to be of interest only to bumetanide users and the French and German bumetanide researchers. I did suggest recently when I published version 5 of Monty’s PolyPill , that it is getting close to the final version.   Some of the potential remaining elements have already been written about in this blog, but I have not finished evaluating them.   Azosemide falls into this category. One theme within this blog has been to increase the “autism effect...